{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T06:01:11Z","timestamp":1787032871123,"version":"build-2736575974"},"reference-count":21,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,3,3]]},"DOI":"10.7759\/cureus.104617","type":"journal-article","created":{"date-parts":[[2026,3,3]],"date-time":"2026-03-03T16:13:11Z","timestamp":1772554391000},"source":"Crossref","is-referenced-by-count":1,"title":["Marked Improvement in Treatment-Intolerant Obsessive-Compulsive Disorder in an Adolescent Using a Glutamatergic Regimen With Dextromethorphan, Piracetam, and Goldenseal Root"],"prefix":"10.7759","author":[{"given":"Ngo","family":"Cheung","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1016\/j.psc.2006.02.012","article-title":"Obsessive-compulsive and spectrum disorders in children and adolescents","volume":"29","author":"Geller DA","year":"2006","unstructured":"Geller DA. Obsessive-compulsive and spectrum disorders in children and adolescents. Psychiatr Clin North Am. 2006, 29:353-70. 10.1016\/j.psc.2006.02.012","journal-title":"Psychiatr Clin North Am"},{"key":"ref2","unstructured":"American Academy of Child and Adolescent Psychiatry. Obsessive-compulsive disorder in children and adolescents. Fact Sheet No. 60. (2012). Accessed. January 2026: https:\/\/www.aacap.org\/AACAP\/Families_and_Youth\/Facts_for_Families\/FFF-Guide\/Obsessive-Compulsive-Disorder-In-Children...."},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.92496","article-title":"Transcranial magnetic stimulation in obsessive-compulsive disorder and adolescent depression: a systematic review of efficacy, safety, and predictors of treatment response","volume":"17","author":"Babu Bodapati NV","year":"2025","unstructured":"Babu Bodapati NV. Transcranial magnetic stimulation in obsessive-compulsive disorder and adolescent depression: a systematic review of efficacy, safety, and predictors of treatment response. Cureus. 2025, 17:e92496. 10.7759\/cureus.92496","journal-title":"Cureus"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaac.2016.07.768","article-title":"Systematic review and meta-analysis: early treatment responses of selective serotonin reuptake inhibitors and clomipramine in pediatric obsessive-compulsive disorder","volume":"55","author":"Varigonda AL","year":"2016","unstructured":"Varigonda AL, Jakubovski E, Bloch MH. Systematic review and meta-analysis: early treatment responses of selective serotonin reuptake inhibitors and clomipramine in pediatric obsessive-compulsive disorder. J Am Acad Child Adolesc Psychiatry. 2016, 55:851-9.e2. 10.1016\/j.jaac.2016.07.768","journal-title":"J Am Acad Child Adolesc Psychiatry"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1038\/mp.2009.50","article-title":"Meta-analysis of the dose-response relationship of SSRI in obsessive-compulsive disorder","volume":"15","author":"Bloch MH","year":"2010","unstructured":"Bloch MH, McGuire J, Landeros-Weisenberger A, Leckman JF, Pittenger C. Meta-analysis of the dose-response relationship of SSRI in obsessive-compulsive disorder. Mol Psychiatry. 2010, 15:850-5. 10.1038\/mp.2009.50","journal-title":"Mol Psychiatry"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.2174\/1875397300802010062","article-title":"Glutamatergic synaptic dysfunction and obsessive-compulsive disorder","volume":"2","author":"Ting JT","year":"2008","unstructured":"Ting JT, Feng G. Glutamatergic synaptic dysfunction and obsessive-compulsive disorder. Curr Chem Genomics. 2008, 2:62-75. 10.2174\/1875397300802010062","journal-title":"Curr Chem Genomics"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.2147\/NDT.S211703","article-title":"Investigating the role of glutamate in obsessive-compulsive disorder: current perspectives","volume":"16","author":"Karthik S","year":"2020","unstructured":"Karthik S, Sharma LP, Narayanaswamy JC. Investigating the role of glutamate in obsessive-compulsive disorder: current perspectives. Neuropsychiatr Dis Treat. 2020, 16:1003-13. 10.2147\/NDT.S211703","journal-title":"Neuropsychiatr Dis Treat"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1038\/npp.2013.150","article-title":"Randomized controlled crossover trial of ketamine in obsessive-compulsive disorder: proof-of-concept","volume":"38","author":"Rodriguez CI","year":"2013","unstructured":"Rodriguez CI, Kegeles LS, Levinson A, et al.. Randomized controlled crossover trial of ketamine in obsessive-compulsive disorder: proof-of-concept. Neuropsychopharmacology. 2013, 38:2475-83. 10.1038\/npp.2013.150","journal-title":"Neuropsychopharmacology"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1177\/02698811241301215","article-title":"Ketamine for treatment-resistant obsessive-compulsive disorder: double-blind active-controlled crossover study","volume":"39","author":"Beaglehole B","year":"2025","unstructured":"Beaglehole B, Glue P, Neehoff S, et al.. Ketamine for treatment-resistant obsessive-compulsive disorder: double-blind active-controlled crossover study. J Psychopharmacol. 2025, 39:23-8. 10.1177\/02698811241301215","journal-title":"J Psychopharmacol"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.4088\/JCP.21m14345","article-title":"Efficacy and safety of AXS-05 (dextromethorphan-bupropion) in patients with major depressive disorder: a phase 3 randomized clinical trial (GEMINI)","volume":"83","author":"Iosifescu DV","year":"2022","unstructured":"Iosifescu DV, Jones A, O'Gorman C, Streicher C, Feliz S, Fava M, Tabuteau H. Efficacy and safety of AXS-05 (dextromethorphan-bupropion) in patients with major depressive disorder: a phase 3 randomized clinical trial (GEMINI). J Clin Psychiatry. 2022, 83:21m14345. 10.4088\/JCP.21m14345","journal-title":"J Clin Psychiatry"},{"key":"ref11","unstructured":"Study of dextromethorphan in OCD and related disorders. (2025). Accessed. January 2026: https:\/\/clinicaltrials.gov\/study\/NCT04899687."},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1007\/s10803-018-3703-x","article-title":"A randomized, placebo-controlled, blinded, crossover, pilot study of the effects of dextromethorphan\/quinidine for the treatment of neurobehavioral symptoms in adults with autism","volume":"50","author":"Chez M","year":"2020","unstructured":"Chez M, Kile S, Lepage C, Parise C, Benabides B, Hankins A. A randomized, placebo-controlled, blinded, crossover, pilot study of the effects of dextromethorphan\/quinidine for the treatment of neurobehavioral symptoms in adults with autism. J Autism Dev Disord. 2020, 50:1532-8. 10.1007\/s10803-018-3703-x","journal-title":"J Autism Dev Disord"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.20944\/preprints202511.1815.v1","article-title":"DXM, CYP2D6-inhibiting antidepressants, piracetam, and glutamine: proposing a ketamine-class antidepressant regimen with existing drugs [Preprint]","author":"Cheung N","year":"2025","unstructured":"Cheung N. DXM, CYP2D6-inhibiting antidepressants, piracetam, and glutamine: proposing a ketamine-class antidepressant regimen with existing drugs [Preprint]. Preprints.org. 2025, 10.20944\/preprints202511.1815.v1","journal-title":"Preprints.org"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1002\/mnfr.200600300","article-title":"Clinical assessment of CYP2D6-mediated herb-drug interactions in humans: effects of milk thistle, black cohosh, goldenseal, kava kava, St. John's wort, and Echinacea","volume":"52","author":"Gurley BJ","year":"2008","unstructured":"Gurley BJ, Swain A, Hubbard MA, et al.. Clinical assessment of CYP2D6-mediated herb-drug interactions in humans: effects of milk thistle, black cohosh, goldenseal, kava kava, St. John's wort, and Echinacea. Mol Nutr Food Res. 2008, 52:755-63. 10.1002\/mnfr.200600300","journal-title":"Mol Nutr Food Res"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1016\/j.phrs.2020.105085","article-title":"Goldenseal (Hydrastis canadensis L.) and its active constituents: a critical review of their efficacy and toxicological issues","volume":"160","author":"Mandal SK","year":"2020","unstructured":"Mandal SK, Maji AK, Mishra SK, Ishfaq PM, Devkota HP, Silva AS, Das N. Goldenseal (Hydrastis canadensis L.) and its active constituents: a critical review of their efficacy and toxicological issues. Pharmacol Res. 2020, 160:105085. 10.1016\/j.phrs.2020.105085","journal-title":"Pharmacol Res"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1046\/j.1525-1497.2001.016009606.x","article-title":"The PHQ-9: validity of a brief depression severity measure","volume":"16","author":"Kroenke K","year":"2001","unstructured":"Kroenke K, Spitzer RL, Williams JB. The PHQ-9: validity of a brief depression severity measure. J Gen Intern Med. 2001, 16:606-13. 10.1046\/j.1525-1497.2001.016009606.x","journal-title":"J Gen Intern Med"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1001\/archinte.166.10.1092","article-title":"A brief measure for assessing generalized anxiety disorder: the GAD-7","volume":"166","author":"Spitzer RL","year":"2006","unstructured":"Spitzer RL, Kroenke K, Williams JB, L\u00f6we B. A brief measure for assessing generalized anxiety disorder: the GAD-7. Arch Intern Med. 2006, 166:1092-7. 10.1001\/archinte.166.10.1092","journal-title":"Arch Intern Med"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1177\/20503121211039098","article-title":"The effect of lemborexant for insomnia disorder","volume":"9","author":"Suzuki H","year":"2021","unstructured":"Suzuki H, Hibino H. The effect of lemborexant for insomnia disorder. SAGE Open Med. 2021, 9:20503121211039098. 10.1177\/20503121211039098","journal-title":"SAGE Open Med"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1038\/nature17998","article-title":"NMDAR inhibition-independent antidepressant actions of ketamine metabolites","volume":"533","author":"Zanos P","year":"2016","unstructured":"Zanos P, Moaddel R, Morris PJ, et al.. NMDAR inhibition-independent antidepressant actions of ketamine metabolites. Nature. 2016, 533:481-6. 10.1038\/nature17998","journal-title":"Nature"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.5281\/zenodo.18175844","article-title":"Multi-method polygenic investigation implicates dysregulated synaptic pruning in the etiology of obsessive-compulsive disorder [Preprint]","author":"Cheung N","year":"2026","unstructured":"Cheung N. Multi-method polygenic investigation implicates dysregulated synaptic pruning in the etiology of obsessive-compulsive disorder [Preprint]. Zenodo. 2026, 10.5281\/zenodo.18175844","journal-title":"Zenodo"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.1067\/mcp.2002.126913","article-title":"Cytochrome P450 phenotypic ratios for predicting herb-drug interactions in humans","volume":"72","author":"Gurley BJ","year":"2002","unstructured":"Gurley BJ, Gardner SF, Hubbard MA, Williams DK, Gentry WB, Cui Y, Ang CY. Cytochrome P450 phenotypic ratios for predicting herb-drug interactions in humans. Clin Pharmacol Ther. 2002, 72:276-87. 10.1067\/mcp.2002.126913","journal-title":"Clin Pharmacol Ther"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/464466-marked-improvement-in-treatment-intolerant-obsessive-compulsive-disorder-in-an-adolescent-using-a-glutamatergic-regimen-with-dextromethorphan-piracetam-and-goldenseal-root","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,3]],"date-time":"2026-03-03T16:13:16Z","timestamp":1772554396000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/464466-marked-improvement-in-treatment-intolerant-obsessive-compulsive-disorder-in-an-adolescent-using-a-glutamatergic-regimen-with-dextromethorphan-piracetam-and-goldenseal-root"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,3]]},"references-count":21,"URL":"https:\/\/doi.org\/10.7759\/cureus.104617","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2026,3,3]]}}}